News headlines about Sanofi (NYSE:SNY) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sanofi earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.4679743610933 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
- Investors Buy Shares of Netflix, Inc. (NFLX) on Weakness (iphonefresh.com)
- Sanofi Shows Improved Relative Price Performance; Still Shy Of Benchmark (investors.com)
- Sanofi Genzyme Continues Driving Revenue Growth in 2Q17 (finance.yahoo.com)
- European Pharma Companies Slip on MS Pricing Probe (finance.yahoo.com)
- Sen. Grassley says Mylan’s $465 million Epi-Pen settlement ‘shortchanges’ taxpayers (cnbc.com)
Shares of Sanofi (NYSE SNY) traded up 0.23% during mid-day trading on Friday, reaching $48.19. 573,279 shares of the company’s stock traded hands. The company has a market cap of $121.03 billion, a price-to-earnings ratio of 11.43 and a beta of 0.88. The company has a 50 day moving average of $47.84 and a 200 day moving average of $46.41. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24.
Sanofi (NYSE:SNY) last released its earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi’s revenue for the quarter was down 2.3% compared to the same quarter last year. Analysts expect that Sanofi will post $3.26 earnings per share for the current fiscal year.
A number of equities research analysts recently issued reports on the stock. Argus increased their target price on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Cowen and Company reissued a “market perform” rating and set a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $54.00.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/sanofi-sny-earning-somewhat-favorable-media-coverage-study-finds-updated-updated-updated.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.